Clinical trials: Synucleinopathy
Parkinson's Disease With End of Dose Wearing Off
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
- Trial name
- NCT00219284
- Testing
- Carbidopa/levodopa/entacapone
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 359 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease, Treadmill
Amplitude and Rate of Intrinsic Feedback During Treadmill Training for Parkinson's Disease
Treadmill training has been shown to be beneficial for reducing motor symptoms of Parkinson's disease (PD). The mechanisms for the therapeutic effects of treadmill training remain unknown.
- Trial name
- NCT01987557
- Testing
- rate group, magnitude treadmill group, regular treadmill walking
- Volunteers
- 48 people
- Sponsor
- Wilfrid Laurier University
Parkinson Disease
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
This study is a fixed dose, dose response study to characterize the dose response for ropinirole PR in early stage PD patients (Hoehn \& Yahr stages I-III).
- Trial name
- TANDEM-662 (NCT01485172)
- Testing
- ropinirole monotherapy
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease, Gait Impairment
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait.
- Trial name
- NCT00526630
- Testing
- Methylphenidate (MPD)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Cincinnati
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Parkinson Disease
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene.
- Trial name
- LIGHTHOUSE (NCT05418673)
- Testing
- BIIB122
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 7 people
- Sponsor
- Biogen
Parkinson's Disease
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2…
- Trial name
- ND0612/003 (NCT01883505)
- Testing
- ND0612, Entacapone
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NeuroDerm Ltd.
Accidental Falls, Fall Due to Loss of Equilibrium
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
The investigators propose a randomized control trial to evaluate long term effects and effectiveness of Moore Balance Brace (MBB) ankle foot orthoses (AFO) in reducing risk of falling in older adults.
- Conditions
- Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes
- Trial name
- NCT02819011
- Testing
- MBB AFO, Control
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Bijan Najafi, PhD
Parkinson's Disease
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3
Varying oral doses of Varenicline (VCN), starting with very low doses, will be administered to participants with Parkinson's Disease (PD) or healthy controls without PD for several days.
- Trial name
- UdallP3 (NCT02933372)
- Testing
- Varenicline
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of…
- Trial name
- ALLAY-LID-II (NCT02153632)
- Testing
- amantadine HCl ER
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
- Trial name
- TEAL (NCT04369430)
- Testing
- AKST4290
- Where
- 22 sites in United States, Estonia and 3 more
- Volunteers
- 110 people
- Sponsor
- Alkahest, Inc.
Parkinson's Disease
Safety and Efficacy of DA-9805 for Parkinson's Disease
This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.
- Trial name
- NCT03189563
- Testing
- DA-9805 45mg, DA-9805 90mg
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Dong-A ST Co., Ltd.
Parkinson's Disease
Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain.
- Trial name
- NCT02610634
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Parkinson Disease, Fall
Community Exercise for Fall Risk in PD
Parkinson's disease (PD) affects approximately 1 million people in the United States and causes significant fall risks. This study aims to develop a community-based exercise program that reduces falls in persons with PD.
- Conditions
- Parkinson Disease, Fall, Exercise
- Trial name
- NCT05940077
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Idaho State University
Parkinson Disease, Cognitive Impairment, Mild
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease.
- Conditions
- Parkinson Disease, Cognitive Impairment, Mild, Speech
- Trial name
- SLAM-PD (NCT04273672)
- Testing
- Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Parkinson Disease
Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease
The present study aims to investigate the effect of transcranial direct current stimulation (tDCS) associated with physiotherapy in parkinson´s rehabilitation.
- Trial name
- NCT01877148
- Testing
- tDCS, Physiotherapy
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Universidade Federal de Pernambuco
Parkinson's Disease, Cognitive Impairment
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
The purpose of this study is to determine the safety and effectiveness of a drug called atomoxetine for the treatment of cognitive impairment for Parkinson 's disease.
- Trial name
- ATM-Cog (NCT01738191)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Parkinson's Disease
Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS
Our recent study (Xie et al, Neurology 2015; 84: 415-420) found that bilateral STN DBS of 60Hz, compared to the traditional 130Hz, decreased the aspiration frequency and swallowing difficulty, freezing of gait (FOG), and other…
- Trial name
- NCT02549859
- Testing
- Deep Brain Stimulation (DBS) at 60 Hz, Deep Brain Stimulation (DBS) at 130 Hz
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Parkinson Disease
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.
- Trial name
- NCT03624920
- Testing
- THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
- Where
- 34 sites in United States, Czechia and 3 more
- Volunteers
- 77 people
- Sponsor
- Theranexus